These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30796021)

  • 1. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
    Sánchez-Martínez D; Baroni ML; Gutierrez-Agüera F; Roca-Ho H; Blanch-Lombarte O; González-García S; Torrebadell M; Junca J; Ramírez-Orellana M; Velasco-Hernández T; Bueno C; Fuster JL; Prado JG; Calvo J; Uzan B; Cools J; Camos M; Pflumio F; Toribio ML; Menéndez P
    Blood; 2019 May; 133(21):2291-2304. PubMed ID: 30796021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.
    Jiménez-Reinoso A; Tirado N; Martinez-Moreno A; Díaz VM; García-Peydró M; Hangiu O; Díez-Alonso L; Albitre Á; Penela P; Toribio ML; Menéndez P; Álvarez-Vallina L; Sánchez Martínez D
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
    Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
    J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
    Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
    Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
    Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia.
    Maciocia PM; Wawrzyniecka PA; Maciocia NC; Burley A; Karpanasamy T; Devereaux S; Hoekx M; O'Connor D; Leon T; Rapoz-D'Silva T; Pocock R; Rahman S; Gritti G; Yánez DC; Ross S; Crompton T; Williams O; Lee L; Pule MA; Mansour MR
    Blood; 2022 Jul; 140(1):25-37. PubMed ID: 35507686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
    Cooper ML; DiPersio JF
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
    Zhang M; Chen D; Fu X; Meng H; Nan F; Sun Z; Yu H; Zhang L; Li L; Li X; Wang X; Wang M; You F; Li Z; Chang Y; Zhou Z; Yan J; Li J; Wu X; Wang Y; Wang Y; Xiang S; Chen Y; Pan G; Xu H; Zhang B; Yang L
    Clin Cancer Res; 2022 Jul; 28(13):2830-2843. PubMed ID: 35435984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains.
    Dai Z; Mu W; Zhao Y; Jia X; Liu J; Wei Q; Tan T; Zhou J
    Mol Ther; 2021 Sep; 29(9):2707-2722. PubMed ID: 34274536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.
    Mamonkin M; Rouce RH; Tashiro H; Brenner MK
    Blood; 2015 Aug; 126(8):983-92. PubMed ID: 26056165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
    Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
    Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.
    Liao C; Wang Y; Huang Y; Duan Y; Liang Y; Chen J; Jiang J; Shang K; Zhou C; Gu Y; Liu N; Zeng X; Gao X; Tang Y; Sun J
    Adv Sci (Weinh); 2023 Sep; 10(27):e2207394. PubMed ID: 37485647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells.
    Fang KK; Lee J; Khatri I; Na Y; Zhang L
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
    Bayón-Calderón F; Toribio ML; González-García S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies.
    Guo Z; Zhang Y; Fu M; Zhao L; Wang Z; Xu Z; Zhu H; Lan X; Shen G; He Y; Lei P
    Front Immunol; 2021; 12():652924. PubMed ID: 33854512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
    Köksal H; Dillard P; Josefsson SE; Maggadottir SM; Pollmann S; Fåne A; Blaker YN; Beiske K; Huse K; Kolstad A; Holte H; Kvalheim G; Smeland EB; Myklebust JH; Inderberg EM; Wälchli S
    Blood Adv; 2019 Apr; 3(8):1230-1243. PubMed ID: 30979721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.